EUCTR2009-015984-15-GB进行中（未招募）1 期
A Phase I/II Safety, Tolerability, Ascending Dose and Dose Frequency Study of Recombinant Human Heparan-N-sulfatase (rhHNS) Intrathecal Administration via an Intrathecal Drug Delivery Device in Patients With Sanfilippo Syndrome Type A (MPS IIIA)
Shire Human Genetic Therapies, Inc. (Shire HGT)0 个研究点目标入组 12 人开始时间: 2010年3月17日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.a.)Patients have a documented deficiency in sulfamidase enzyme activity of =10% of the lower limit of the normal range as measured in fibroblasts or leukocytes (based on measurements by a laboratory that is acceptable to Shire HGT).
- •AND EITHER b or C
- •b.)Patients have a normal enzyme activity level of at least 1 other sulfatase (to rule out multiple sulfatase deficiency) as measured in fibroblasts or leukocytes (based on measurements by a laboratory that is acceptable to Shire HGT).
- •c.) Patients have 2 documented mutations (based on assessments by a laboratory that is acceptable to Shire HGT).
- •2.The patient is =3 years of age and has a developmental age above 1 year (developmental age will be determined by the screening neurocognitive and developmental tests).
- •3.Patients must be medically stable, in the opinion of the Investigator, to accommodate the protocol requirements, including travel, assessments, and IDDD surgery, without placing an undue burden on the patient/patient's family.
- •4.The patient’s parent(s) or legal guardian must have voluntarily signed an Institutional Review Board/Independent Ethics Committee-approved informed consent form
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 15
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.The patient has significant non-MPS IIIA related central nervous system (CNS) impairment or behavioral disturbances that would confound the scientific integrity or interpretation of study assessments, as determined by the Investigator.
- •2.The patient has MPS IIIA behavioral-related issues, as determined by the Investigator that would preclude performance of study neurocognitive and developmental testing procedures.
- •3.The patient is pregnant, breast feeding, or is a female patient of childbearing potential who will not or cannot comply with the use of an acceptable method of birth control
- •4. The patient is blind and/or deaf
- •5.The patient has any known or suspected hypersensitivity to anesthesia or is thought to have an unacceptably high risk for anesthesia due to airway compromise or other conditions.
- •6.The patient or the patient's family has a history of neuroleptic malignant syndrome, malignant hyperthermia, or other anesthesia-related concerns.
- •7.The Investigator may choose to exclude patients who have had complications resulting from prior lumbar punctures.
- •8.The patient has a CNS shunt.
- •9.The patient has skeletomuscular/spinal abnormalities or other contraindications for the surgical implantation of the IDDD.
- •10.The patient has a history of poorly controlled seizure disorder.
- •11.The patient is currently receiving psychotropic or other medications, which in the Investigator’s opinion, would be likely to substantially confound test results and the dose and regimen of which cannot be kept constant throughout the study.
- •12.The patient cannot sustain absence from aspirin, non-steroidal medications, or medications that affect blood clotting within 1 week prior to a relevant study-related procedure (eg, device implantation if applicable), or has ingested such medications within 1 week before any procedures in which any change in clotting activity would be deleterious.
- •13.The patient has received treatment with any investigational drug or a device intended as a treatment for MPS IIIA within the 30 days prior to, or during the study, or is currently enrolled in another study that involves an investigational drug or device (screening through safety follow-up contact).
- •14.The patient has received a hematopoietic stem cell or bone marrow transplant.
- •15.The patient’s parent(s), or patient’s legal guardian(s) is/are unable to provide consent or the patient cannot provide assent,
研究者
相似试验
进行中（未招募）
1 期
A Phase I/II safety and tolerability dose escalation study following the autologous infusion of expanded adult haematopoietic stem cells to patients with established myocardial ischaemia.EUCTR2006-000280-28-GBImperial College London40
进行中（未招募）
1 期
A phase I/II safety and tolerability dose escalation study following the autologous infusion of expanded adult haemopoietic stem cells to patients with liver insufficiency - Dose escalation autologous stem cell studyChronic liver insufficiencyMedDRA version: 9.1 Level: LLT Classification code 10024667 Term: Liver cirrhosisMedDRA version: 9.1 Level: LLT Classification code 10024670 Term: Liver disorderEUCTR2005-001222-83-GBImperial College London5
进行中（未招募）
1 期
A clinical study performed with increasing doses (single dose per patient) to evaluate safety, tolerability and pharmacokinetic of NicaPlant® in aneurysmal subarachnoid haemorrhage patients needing to undergo an aneurysm clipping operatioAneurysmal subarachnoid haemorrhageMedDRA version: 20.1 Level: PT Classification code 10008111 Term: Cerebral haemorrhage System Organ Class: 10029205 - Nervous system disordersEUCTR2016-004521-17-ATBIT Pharma GmbH14
进行中（未招募）
1 期
A Phase 1/2 study to evaluate the safety and efficacy of BMN 270 gene therapy in patients with severe Haemophilia AHaemophilia AEUCTR2014-003880-38-GBBioMarin Pharmaceutical Inc.15
已完成
1 期
Phase I Dose-escalation, Safety / Tolerability and Preliminary Efficacy Study of Intratumoral Administration of GEN0101 in Patients with Advanced Melanoma.Advanced MelanomaJPRN-UMIN000012943Department of Dermatology Course of Integrated Medicine Graduate School of Medicine, Osaka University15